Prevents hypokalemia with or without metabolic alkalosis. ANDA 209662, held by Upsher Smith Labs. Potassium Chloride.
As of Nov 15, 2026, ANDA 209662 (Klor-Con), held by Upsher Smith Labs, was first approved by FDA on Oct 23, 2017, with 2 approved supplements and 0 published complete response letters.
Klor-Con powder (potassium chloride) is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride is a potassium salt
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Klor-Con20MEQ · for solution;oral | Potassium Chloride | Rx |
| Apr 26, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 6, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 23, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
